Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
American Journal of Physiology-Cell Physiology · 01.05.2025 · 328 (5) · C1637-C1666
DOI: 10.1152/ajpcell.00951.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, erschienen am 01.05.2025. Verfasst von Mohammad Shafi Kuchay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Medanta-The Medicity, Gurugram, India. Hauptthemen laut MEDLINE: Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 305 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as the leading cause of chronic liver disease worldwide, reflecting the global epidemics of obesity, metabolic syndrome, and type 2 diabetes. Beyond its strong association with excess adiposity, MASLD encompasses a heterogeneous population that includes individuals with normal body weight (“lean MASLD”) highlighting the complexity of its pathogenesis. This disease results from a complex interplay between genetic susceptibility, epigenetic modifications, and environmental factors, which converge to disrupt metabolic homeostasis. Adipose tissue dysfunction and insulin resistance trigger an overflow of lipids to the liver, leading to mitochondrial dysfunction, oxidative stress, and hepatocellular injury. These processes promote hepatic inflammation and fibrogenesis, driven by cross talk among hepatocytes, immune cells, and hepatic stellate cells, with key contributions from gut-liver axis perturbations. Recent advances have unraveled pivotal molecular pathways, such as transforming growth factor-β signaling, Notch-induced osteopontin, and sphingosine kinase 1-mediated responses, that orchestrate fibrogenic activation. Understanding these interconnected mechanisms is crucial for developing targeted therapies. This review integrates current knowledge on the pathophysiology of MASLD, emphasizing emerging concepts such as lean metabolic dysfunction-associated steatohepatitis (MASH), epigenetic alterations, hepatic extracellular vesicles, and the relevance of extrahepatic signals. It also discusses novel therapeutic strategies under investigation, aiming to provide a comprehensive and structured overview of the evolving MASLD landscape for both basic scientists and clinicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Medanta-The Medicity, Gurugram, India.
- Institute of Digestive and Hepatobiliary Sciences, Medanta-The Medicity Hospital, Gurugram, India.
- Group of Obesity, Diabetes & Metabolism, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
ORCID-Profile: Mohammad Shafi Kuchay, Bruno Ramos-Molina
Zitieren
APA
Kuchay, M. S., Choudhary, N. S., & Ramos-Molina, B. (2025). Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. American Journal of Physiology-Cell Physiology, 328(5), C1637-C1666. https://doi.org/10.1152/ajpcell.00951.2024
Vancouver
Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. American Journal of Physiology-Cell Physiology. 2025;328(5):C1637-C1666. doi:10.1152/ajpcell.00951.2024
BibTeX
@article{Kuchay2025,
author = {Kuchay, Mohammad Shafi and Choudhary, Narendra Singh and Ramos-Molina, Bruno},
title = {Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
volume = {328},
number = {5},
pages = {C1637--C1666},
doi = {10.1152/ajpcell.00951.2024}
}
EUVIMED